211 related articles for article (PubMed ID: 21070399)
1. Strategies to reduce transfusion acquired vCJD.
Wallis JP
Transfus Med; 2011 Feb; 21(1):1-6. PubMed ID: 21070399
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of prion filtration of red blood cells to reduce the risk of transfusion-transmitted variant Creutzfeldt-Jakob disease in the Republic of Ireland.
Teljeur C; Flattery M; Harrington P; O'Neill M; Moran PS; Murphy L; Ryan M
Transfusion; 2012 Nov; 52(11):2285-93. PubMed ID: 22486387
[TBL] [Abstract][Full Text] [Related]
3. Variant Creutzfeldt-Jakob disease in a transfusion recipient: coincidence or cause?
Chohan G; Llewelyn C; Mackenzie J; Cousens S; Kennedy A; Will R; Hewitt P
Transfusion; 2010 May; 50(5):1003-6. PubMed ID: 20230536
[TBL] [Abstract][Full Text] [Related]
4. Transfusion transmission of human prion diseases.
Zou S; Fang CT; Schonberger LB
Transfus Med Rev; 2008 Jan; 22(1):58-69. PubMed ID: 18063192
[TBL] [Abstract][Full Text] [Related]
5. Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study.
Hewitt PE; Llewelyn CA; Mackenzie J; Will RG
Vox Sang; 2006 Oct; 91(3):221-30. PubMed ID: 16958834
[TBL] [Abstract][Full Text] [Related]
6. UK approach to assessing assays and filters designed to reduce the risk of transfusion-transmitted vCJD.
Thomas S; Turner ML; Williamson LM
Transfus Clin Biol; 2013 Sep; 20(4):405-11. PubMed ID: 23928183
[TBL] [Abstract][Full Text] [Related]
7. Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products.
Ludlam CA; Turner ML
Br J Haematol; 2006 Jan; 132(1):13-24. PubMed ID: 16371015
[TBL] [Abstract][Full Text] [Related]
8. vCJD and blood transfusion in the United Kingdom.
Hewitt P
Transfus Clin Biol; 2006 Nov; 13(5):312-6. PubMed ID: 17188541
[TBL] [Abstract][Full Text] [Related]
9. Dealing with the uncertain risk of variant Creutzfeldt-Jakob disease transmission by coagulation replacement products.
Millar CM; Makris M
Br J Haematol; 2012 Aug; 158(4):442-52. PubMed ID: 22775486
[TBL] [Abstract][Full Text] [Related]
10. Impact of vCJD on blood supply.
Seitz R; von Auer F; Blümel J; Burger R; Buschmann A; Dietz K; Heiden M; Hitzler WE; Klamm H; Kreil T; Kretzschmar H; Nübling M; Offergeld R; Pauli G; Schottstedt V; Volkers P; Zerr I
Biologicals; 2007 Apr; 35(2):79-97. PubMed ID: 17320412
[TBL] [Abstract][Full Text] [Related]
11. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products.
Turner ML; Ludlam CA
Br J Haematol; 2009 Jan; 144(1):14-23. PubMed ID: 18950452
[TBL] [Abstract][Full Text] [Related]
12. ['Variant of Creutzfeldt-Jacob disease and blood transfusion'; report of the Dutch Health Council].
van Aken WG
Ned Tijdschr Geneeskd; 2001 Jul; 145(30):1444-7. PubMed ID: 11503311
[TBL] [Abstract][Full Text] [Related]
13. An overview of prion biology and the role of blood filtration in reducing the risk of transfusion-transmitted variant Creutzfeldt-Jakob disease.
Cervia JS; Sowemimo-Coker SO; Ortolano GA; Wilkins K; Schaffer J; Wortham ST
Transfus Med Rev; 2006 Jul; 20(3):190-206. PubMed ID: 16787827
[TBL] [Abstract][Full Text] [Related]
14. [Transfusion risk analysis with regard to vCJD in France].
Martin M; Legras JF; Pouchol E; Trouvin JH
Transfus Clin Biol; 2006 Nov; 13(5):298-303. PubMed ID: 17188540
[TBL] [Abstract][Full Text] [Related]
15. The risk of variant Creutzfeldt-Jakob disease among UK patients with bleeding disorders, known to have received potentially contaminated plasma products.
Zaman SM; Hill FG; Palmer B; Millar CM; Bone A; Molesworth AM; Connor N; Lee CA; Dolan G; Wilde JT; Gill ON; Makris M
Haemophilia; 2011 Nov; 17(6):931-7. PubMed ID: 21342369
[TBL] [Abstract][Full Text] [Related]
16. Variant Creutzfeldt-Jakob disease (vCJD). Precautionary measures against the risk of transmission of the agent of vCJD by blood transfusion.
Wkly Epidemiol Rec; 2000 Nov; 75(47):377-9. PubMed ID: 11144617
[No Abstract] [Full Text] [Related]
17. Universal white blood cell reduction in Europe: has transmission of variant Creutzfeldt-Jakob disease been prevented?
Vamvakas EC
Transfus Med Rev; 2011 Apr; 25(2):133-44. PubMed ID: 21345641
[TBL] [Abstract][Full Text] [Related]
18. The impact of variant CJD on transfusion practices in the UK.
Boulton F
Transfus Apher Sci; 2003 Apr; 28(2):107-16. PubMed ID: 12679113
[TBL] [Abstract][Full Text] [Related]
19. Variant CJD and blood transfusion: are there additional cases?
Davidson LR; Llewelyn CA; Mackenzie JM; Hewitt PE; Will RG
Vox Sang; 2014 Oct; 107(3):220-5. PubMed ID: 24916465
[TBL] [Abstract][Full Text] [Related]
20. The application of the precautionary principle to the blood system: the Canadian blood system's vCJD donor deferral policy.
Wilson K; Wilson M; Hébert PC; Graham I
Transfus Med Rev; 2003 Apr; 17(2):89-94. PubMed ID: 12733102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
